Information about opioids
In July 2017, ExamOne announced it offers an expanded opioid panel for life insurers. For the last three decades, ExamOne has offered two main options (see table below) for full urine drug screens to help insurers identify risk in the insurance population.
These screens were developed in the 1980s and are recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA, formerly the National Institute on Drug Abuse, NIDA) for the testing of certain federal employees, as well as specified Department of Transportation (DOT) regulated occupations.
The expanded panel detects semi-synthetic opioid use and includes the following drugs: codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl and heroin. As with all drug testing, positive screens are confirmed with gas chromatography/mass spectrometry (gc/ms).
Learn more about the risks and impacts of opioid abuse in America
The risks of opioid for life insurersopens PDF file
One in 4 individuals combine opioids and benzodiazepines
Illicit drug use in the US is at the highest rate in a decade
More laboratory resources
We are committed to providing you with the resources you need to underwrite with full confidence. This section highlights specific laboratory tests and why you should include them in your standard insurance testing panel.
Kidney disease and mortality marker
Cystatin Copens PDF file
Prescription and drugs of abuse marker
Opioidsopens PDF file
Diabetes and mortality marker
Hemoglobin A1copens PDF file
Microalbuminopens PDF file
Congestive heart failure marker
NT-proBNPopens PDF file
Prostate specific antigen
PSAopens PDF file